Enthera Pharmaceuticals Srl raises €28m in Series A financing
Italian start-up Enthera Pharmaceuticals has raised €28m to advance restorative therapy for type 1 diabetes and inflammatory bowel disease.
The round was co-led by the company’s seed investor Sofinnova Partners and new investor AbbVie Inc., Several Italian investors and the JDRF T1D Fund also contributed.
The spin-off from BiovelocITA, Italy’s first biotech accelerator founded by Sofinnova Partners and serial entrepreneurs Silvano Spinelli and Gabriella Camboni, announced it will use the proceeds to advance its pipeline, Ent001, an IGFBP3/TMEM219 blocker, to clinical proof of principle (Phase Ib) for type 1 diabetes, gastrointestinal diseases.
Enthera was formed in 2016 on the basis of research by scientific founders Prof. Paolo Fiorina and Dr. Francesca D’Addio.
SLAS - Alexandra Csuport Photography
Phabioc GmbH